LYTIX BIOPHARMA ASA: årsregnskap 2017 vs 2016
Grew 7% on revenue
approved 2018-06-26; registry 2018-07-07; journal 2018 628223
Summary
What changed
Comparing Årsregnskap 2017 with 2016 for LYTIX BIOPHARMA ASA. Revenue 13.17m NOK → 14.15m NOK (+7.4%). Net result -67.83m NOK → -63.36m NOK. Equity 29.79m NOK → 11.79m NOK.
On the constructive side: revenue rose; net result improved; cash rose. Pressures included: operating result weakened; equity eroded.
Also worth watching: paid-in equity reduced; book investments changed. All figures are taken from the published annual accounts for LYTIX BIOPHARMA ASA.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 13.17m NOK to 14.15m NOK (+7.4% YoY). Calculated
-
↑
Net result improved
Net result -67.83m NOK → -63.36m NOK (net margin -514.9% → -447.8%). Calculated
-
↑
Cash rose
Bank deposits 18.05m NOK → 34.96m NOK (+93.7% YoY). Calculated
What deteriorated
-
↓
Operating result weakened
Operating result -64.47m NOK → -77.86m NOK (op. margin -489.4% → -550.4%). Calculated
-
↓
Equity eroded
Book equity 29.79m NOK → 11.79m NOK (equity ratio 72.4% → 25.0%). Calculated
Things to notice
-
·
Paid-in equity reduced
Paid-in equity fell 29.79m NOK → 11.79m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Book investments changed
Investment / intangible book value 9.36m NOK → 0 NOK. Reported fact